RxAdvocate August, 2021 — Newsletter

COVID-19 Vaccine Quantity Limit Increased – Allowing Third Dose

The FDA has expanded the emergency use authorization for both the Moderna and Pfizer/BioNTech COVID-19 vaccines to allow immunocompromised patients to receive a third dose of the vaccine. Patients eligible for the third vaccine dose represent approximately 3% of the population and would be used in the hopes that the additional dose can further boost the immune response if exposed to the COVID-19 virus. Studies support the third dose of vaccine in these select patients, as a decreased immunogenicity has been observed after the two dose series when compared to those that do not have a compromised immune system. The individuals targeted for additional vaccination are still encouraged to follow suggested preventative measures to decrease exposure risk. Eligible patients should wait at least 28 days since their second vaccine to have the additional dose administered. Adverse effects with the third dose are currently the same as with the first and second vaccine. The use of the Johnson & Johnson vaccine is not included in this expanded approval.

To read more click here!

RxConnection Organizational Announcements

Please join us in welcoming Christina Hollis! She is joining RxConnection as an Account Manager.Christina has 5 years’ experience in PBM and 12 years’ experience in account management. Prior to joining RxConnection, she managed accounts for US-Rx Care, Elixir, and Everyday Health, ensuring quick turnarounds for plan design, benefit changes and clinical inquiries, as well as assisting with enhancing marketing performance and online visibility.Christina graduated with a B.A. in Promotional Communications from Cleveland State University.